An interventional study of ExerciseRx intervention in Multiple Sclerosis (MS), Fatigue and Physical Inactivity, sponsored by University of Washington. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-22.
Sponsored by University of Washington · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Multiple Sclerosis by University of Washington — 7 open to participants now, 7 under way, none of them phase 3. Multiple Sclerosis · University of Washington.
Among the 28 studies in Multiple Sclerosis by University of Washington, this one is the 15th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2024, is one of 23 with no phase, and was the 22nd registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →7 of the 28 studies in Multiple Sclerosis by University of Washington are open now, in 1 country. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 21–70
University of Washington · Sites in United States
Ages 18–70
University of Washington · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1
First in 2008; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 106 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 112 across the 25 interventional studies, 120 across the 3 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.
4 of the studies in Multiple Sclerosis by University of Washington that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06809192University of WashingtonFactorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue | 2026-12-31 |
| NCT07673354University of WashingtonHome-based Spinal Cord Stimulation for Hand & Arm Function in MS | 2027-03-01 |
| NCT07723599University of WashingtonCombating Age-related Failure of Myelination in Multiple Sclerosis: An Exploratory Study | 2027-06 |
| NCT07636434University of WashingtonMy MS Toolkit: An Internet-Based Depression Self-Management Program for Adults Living With Multiple Sclerosis | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies in Multiple Sclerosis by University of Washington, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to advance the scientific understanding and potential future implementation of physical activity promotion by testing the efficacy of a phone-based app for increasing activity in insufficiently active patients with multiple sclerosis (MS).
This study aims to test the efficacy of ExerciseRx, a free software platform designed to increase physical activity in people with multiple sclerosis (PwMS). Exercise is crucial for managing MS symptoms and overall health, but approximately 80% of PwMS do not get enough physical activity due to barriers like physical limitations, common MS symptoms, and lack of community exercise facilities. ExerciseRx translates clinically relevant activity data collected by personal smart devices into actionable metrics on a dashboard within the Epic electronic health record, allowing healthcare providers to prescribe and monitor tailored physical activity solutions for their patients. This study will test the effects of ExerciseRx in a sample of inactive PwMS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants use the ExerciseRx app to meet personalized daily step targets and weekly goals. They will receive MS Exercise and Physical Activity Recommendations and complete in-app surveys about barriers to being active and physical activity level. The ExerciseRx app will adjust the personalized step count goals based on percentage met of the previous week goal and providers will send supportive messages based on participant activity. Participants will complete validated self-report assessments. Providers may also provide participants with additional guidance, make referrals, or schedule telemedicine or in-person clinic follow ups if needed to support the participant's physical activity progression.
Other: ExerciseRx intervention
Participants receive MS Exercise and Physical Activity Recommendations, will continue typical physical activity, and complete validated self-report assessments. At the end of 26 weeks, staff will offer the participants the ExerciseRx intervention protocol.
ExerciseRx is a cloud-based, HIPPA-compliant free software platform created for healthcare providers to prescribe and monitor physical activity as part of routine care. ExerciseRx translates clinically relevant activity data collected by the patient's existing personal smart devices (Android or iOS phone) into actionable metrics on a dashboard within the Epic electronic health record. Providers then use the platform to prescribe physical activity tailored to patients' ability levels and preferences. The platform incorporates behavior change strategies, including motivational feedback and nudges. It also facilitates a feedback loop with the provider, fostering caring patient-provider connections around activity promotion and behavior change. ExerciseRx leverages patients' personal smartphone capabilities to track, quantify, and tailor personalized physical activity solutions, which makes it more readily scalable as a solution across diverse patient populations.
Also known as: Exercise Intervention, Best Practice, App-Based Intervention, Interview, Questionnaire Administration
Physical activity: daily average step count
Increase in physical activity measured by daily average step count measured by ExerciseRx app. Increase in physical activity will be measured and compared between the ExerciseRx and usual care participants.
Time frame: Baseline and week 13
Activity volume
Increase in activity volume will be measured by International Physical Activity Questionnaire-Short. Increase in activity volume will be measured by the total metabolic equivalent minutes of activity per week using the International Physical Activity Questionnaire-Short and compared between the ExerciseRx and usual care participants.
Time frame: Baseline, weeks 13 and 26
Minutes/week of moderate intensity aerobic activity
Measured using Physical Activity Vital Sign (PAVS), 2 items assessing the number of minutes per week a participant engages in moderate to strenuous intensity activity. Will determine the percentage of participants in each group that meet current activity guidelines of \>150min/week of moderate to strenuous physical activity. Total minutes per week of physical activity (#1 multiplied by #2). Increase in minutes/week of moderate intensity aerobic activity will be measured by PAVS and compared between the ExerciseRx and usual care participants.
Time frame: Baseline, weeks 13 and 26
Fatigue - PROMIS Fatigue-MS Short Form 8a
8 items assessing fatigue scored on a T-score metric, with a mean of 50 and a standard deviation (SD) of 10; higher scores indicate higher fatigue. The T-score metric is referenced to the US general population, e.g. a T-score of 40 would be one SD below the US general population. Compared between the ExerciseRx and usual care participants.
Time frame: Baseline, weeks 13 and 26
Pain intensity - PROMIS Pain Intensity Short Form 3a
3 items assessing pain intensity over the past seven days. A 5-point (from 1= Had no pain to 5= Very severe) rating scale is used in each of the 3 items. Higher results mean higher intensity of pain. Compared between the ExerciseRx and usual care participants.
Time frame: Baseline, weeks 13 and 26
Depressive symptom severity - PROMIS Depression Short Form 8a
8-item PROMIS depression questionnaire related to depressed mood in the past 7 days. Each question is rated on a five-point scale from 1=Never to 5=Always. Compared between the ExerciseRx and usual care participants.
Time frame: Baseline, weeks 13 and 26
Sleep disturbance - PROMIS Sleep Disturbance Short Form 6a
6 items assessing sleep disturbance. Each question is answered with a score of 1-5 (varies). The raw score is the sum of each item and ranges from 6-30. The raw score is converted to a T-score ranging from 31.7 to 76.1, with a standard deviation of 10. Higher T-scores indicate greater sleep disturbance. Compared between the ExerciseRx and usual care participants.
Time frame: Baseline, weeks 13 and 26
Physical functioning - PROMIS Physical Function 10a
10-item questionnaire assessing current self-reported physical function. Raw scores range from 10 to 50 and can be translated into T-scores, with a mean of 50 and a standard deviation of 10, for comparison with the U.S. general population mean; for this study, all reported PF-10a scores are T-scores. A higher T-score represents better physical function. Compared between the ExerciseRx and usual care participants.
Time frame: Baseline, weeks 13 and 26
Pain interference - PROMIS Pain Interference Scale Short Form 6a
6-item questionnaire examining the impact of pain on valued areas of an individual's life (e.g., how much did pain interfere with your day to day activities) on a scale of 1=Not at all to 5=Very much. Higher results mean higher interference of pain. Compared between the ExerciseRx and usual care participants.
Time frame: Baseline, weeks 13 and 26
Social participation - PROMIS Satisfaction with Social Roles and Activities Short Form 8a
8-item questionnaire assessing satisfaction with performing one's usual social roles and activities. Each question has five response options on a scale of 1=Not at all to 5=Very much. Sum the values of the response to each question to find the total raw score. Compared between the ExerciseRx and usual care participants.
Time frame: Baseline, weeks 13 and 26
Social participation - PROMIS Ability to Participate in Social Roles and Activities Short Form 8a
8-item questionnaire assessing the perceived ability to perform one's usual social roles and activities. Items are worded negatively in terms of perceived limitations with responses reverse-coded so that higher scores represent fewer limitations (better abilities). The item bank does not use a time frame (e.g. over the past seven days) when assessing ability to participate in social roles and activities. Each question has five response options on a scale of 1=Never to 5=Always. Compared between the ExerciseRx and usual care participants.
Time frame: Baseline, weeks 13 and 26
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2024; primary completion for Apr 2025, 14 months later.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 14 months is below that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.